Observational Study Evaluating Blood‐Based Biomarker Use for Confirmatory Alzheimer's Disease Diagnosis in Real‐World Clinical Practice Within the United States
This study will describe time to final biomarker-confirmed diagnosis for BBMs and other current SOC biomarkers. These findings will characterize the evolving patient journey through the AD diagnostic pathway, from diagnoses with BBMs and current SOC, possibly highlighting potential benefits of BBMs. Reference 1. Schindler SE, et al. Nat Rev Neurol. 2024;20(7):426-439.
Authors
- Soeren Mattke (ORCID: https://orcid.org/0000-0003-4666-9132)
- Feride Frech (ORCID: https://orcid.org/0000-0002-1992-1112)
- Christine Divers
- Leah L. Zullig (ORCID: https://orcid.org/0000-0002-6638-409X)
- Daryl Jones
- Jo Vandercappellen (ORCID: https://orcid.org/0000-0001-8073-5493)
- Nicholas A. Giordano (ORCID: https://orcid.org/0000-0003-0112-6214)
- Michelle M. Mielke (ORCID: https://orcid.org/0000-0001-7177-1185)
- Hideki Toyosaki
- Douglas R. Galasko
- Harald Hampel
- Marwan N. Sabbagh
Institutions
- University of Southern California (US)
- Barrow Neurological Institute (US)
- Duke University (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Eisai (United States) (US)
- Premier Research Group (US)
- Wake Forest University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099857
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00